Literature DB >> 6223643

Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis.

T L Whiteside, Y Kumagai, A D Roumm, R Almendinger, G P Rodnan.   

Abstract

Three different in vitro assays--immunofluorescence with monoclonal anti-T cell reagents, enumeration of T gamma cells, and nonspecific suppressor cell function--were used for the analysis of suppressor lymphocytes in the circulation of 28 patients with progressive systemic sclerosis (PSS, scleroderma) and 20 normal individuals. Both OKT8+ and T gamma lymphocytes were significantly reduced (P less than 0.001 and P less than 0.02, respectively) in patients with PSS compared with controls. The OKT4/OKT8 ratio was increased (P less than 0.02). However, the mean suppressor cell index (SCI) of 1.9 (range 0.4-6.6) for patients with PSS was not significantly different (P greater than 0.05) from the SCI of 2.9 (range 1.2-14) for controls. Eleven of the patients had depressed suppressor cell function as indicated by the index value of less than 1.2. In only 5 of these patients, simultaneously measured T gamma and OKT8+ cells were reduced and OKT4+ lymphocytes were concomitantly increased. There were no significant correlations between the numbers of T gamma or OKT8+ cells and the SCI in patients and controls. Neither depressed suppressor cell function nor the OKT4+/OKT8+ ratio greater than 4.2 (greater than 2 SD of normal) in the patients could be related to other immunologic findings, to disease duration and severity, or to involvement of internal organs. These results suggest that depressed suppressor cell activity and immunoregulatory T cell imbalance in PSS may not be directly related to the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223643     DOI: 10.1002/art.1780260704

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.

Authors:  Aharon Kessel; Itzhak Rosner; Michael Rozenbaum; Devy Zisman; Anca Sagiv; Zehava Shmuel; Edmond Sabo; Elias Toubi
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

3.  An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.

Authors:  N Giordano; G Biasi; A Taddeo; R Marcolongo; D Bertelletti
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

4.  Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies.

Authors:  A Kahan; A Kahan; F Picard; C J Menkès; B Amor
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

5.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

Review 6.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

7.  Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.

Authors:  A Kahan; A Kahan; C J Menkes; B Amor
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

8.  CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.

Authors:  R Gorla; P Airò; A Malagoli; G Carella; E Prati; D Brugnoni; F Franceschini; R Cattaneo
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

9.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis).

Authors:  A J Barnett; B D Tait; M A Barnett; B H Toh
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.